Sun Pharma Ltd. has declared the results of Q2 FY16
Company has posted not good results. On the consolidated basis, for the current quarter ended September 30, 2015 company has reported 41.1% decline & 14.7% rise in net profit and 46% decline & 11.5% rise (ex. Exceptional items) in Profit after tax as compared to for the same quarter in the previous year ended September 30, 2014 and for previous quarter ended June 30, 2015. Net Revenues of the company has decreased by 14.7% on Y-O-y basis and increased marginally by 4.3% on Q-o-Q basis.
Company had incurred exceptional losses of 685 cr. in previous quarter ended June 30, 2015. Exceptional expenses are not ordinary expenses and occur rarely and have no impact in future earnings. So we have filtered those effects. Latest Key Indicators of the stock are as follows:
| Key Market Indicators (Consolidated) | |
| Latest Date | 06-Nov-2015 |
| Latest Price (Rs) | 803.70 |
| Previous Close (Rs) | 815.85 |
| 1 Day Price Var% | -1.49 |
| 1 Year Price Var% | -9.86 |
| 52 Week High (Rs) | 1200.70 |
| 52 Week Low (Rs) | 798.80 |
| Beta | 0.80 |
| Face Value (Rs) | 1.00 |
| Industry PE | 31.66 |
| TTM Period | 201509 |
| TTM EPS(Rs) | 16.20 |
| TTM CEPS(Rs) | 25.55 |
| Price/TTM CEPS(x) | 31.46 |
| TTM PE (x) | 49.61 |
| Price/BV(x) | 7.36 |
| EV/TTM EBIDTA(x) | 26.04 |
| EV/TTM Sales(x) | 8.06 |
| Dividend Yield% | 0.37 |
| MCap/TTM Sales(x) | 8.14 |
| Latest Book Value (Rs) | 109.25 |
| Market Cap (Rs. In Crores) | 193413.30 |
| EV (Rs. In Crores) | 191411.37 |
| Latest no. of shares (In Crores) | 240.65 |
Comparison of quarterly results with previous quarter (Q-o-Q) and the same quarter of last year (Y-o-Y) is below:
| DESCRIPTION | Sep-15 | Sep-14 | Var% | Jun-15 | Var% |
| Net Sales | 6,803 | 7,979 | -14.7 | 6,522 | 4.3 |
| Other operating income | 34 | 60 | -42.9 | 235 | -85.4 |
| Net Sales & Other Operating Income | 6,837.61 | 8,039.37 | -14.95 | 6,757.58 | 1.2 |
| Total Expenditure | 4,904 | 4,973 | -1.4 | 4,908 | -0.1 |
| PBIDT (Excl OI) | 1,934 | 3,066 | -36.9 | 1,850 | 4.5 |
| Other Income | 191 | -31 | 718.6 | 105 | 81.6 |
| Operating Profit | 2,125 | 3,035 | -30.0 | 1,955 | 8.7 |
| Interest | 148 | 162 | -8.2 | 123 | 20.7 |
| Exceptional Items | -685 | ||||
| PBDT | 1,977 | 2,874 | -31.2 | 1,147 | 72.3 |
| Depreciation | 271 | 269 | 0.8 | 240 | 12.9 |
| PBT | 1,705 | 2,605 | -34.5 | 907 | 88.1 |
| Tax | 335 | 279 | 20.1 | 227 | 47.9 |
| Profit After Tax | 1,370 | 2,325 | -41.1 | 680 | 101.5 |
| Profit After Tax (Excluding Exceptional Items) | 1,370 | 2,325 | -41.1 | 1,194 | 14.7 |
| Minority Interest | -270 | -274 | 1.4 | -201 | 34.7 |
| Shares of Associates | 7 | -1 | 1038.7 | 0 | |
| Consolidated Net Profit | 1,107 | 2,050 | -46.0 | 479 | 131.1 |
| Net Profit (Excluding Exceptional Items) | 1,107 | 2,050 | -46.0 | 993 | 11.5 |
| Adj. EPS | 4.60 | 9.90 | -53.5 | 1.99 | 131.2 |
| Adj. EPS (Excluding Exceptional Items) | 4.60 | 9.90 | -53.5 | 4.13 | 11.5 |
| PBIDTM% (Excl OI) | 28.3 | 38.1 | -25.9 | 27.4 | 3.3 |
| PBIDTM% | 31.1 | 37.8 | -17.7 | 28.9 | 7.4 |
| PBDTM% | 28.9 | 35.7 | -19.1 | 17.0 | 70.4 |
| PBTM% | 24.9 | 32.4 | -23.0 | 13.4 | 85.8 |
| PATM% | 20.0 | 28.9 | -30.7 | 10.1 | 99.2 |
| PATM% (Excluding Exceptional Items) | 20.04 | 28.92 | -30.7 | 17.67 | 13.4 |
